Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4051608 | 1.00 | NFE2L2 (0.40) | NFE2L2ADORA2AGPR119PIK3R1PIK3CA | |
| SCHEMBL4060472 | 0.92 | PIK3R1 (0.40) | NFE2L2ADORA2APIK3R1PIK3CAPGR | |
| SCHEMBL4060467 | 0.92 | PIK3R1 (0.40) | NFE2L2ADORA2APIK3R1PIK3CAPGR | |
| SCHEMBL4062200 | 0.89 | PIK3R1 (0.44) | NFE2L2ADORA2AGPR119PIK3R1PIK3CA | |
| SCHEMBL4062204 | 0.89 | PIK3R1 (0.44) | NFE2L2ADORA2AGPR119PIK3R1PIK3CA | |
| SCHEMBL4062300 | 0.83 | NFE2L2 (0.48) | NFE2L2 | |
| SCHEMBL4062306 | 0.83 | NFE2L2 (0.48) | NFE2L2 | |
| SCHEMBL4049941 | 0.81 | PIK3R1 (0.46) | NFE2L2ADORA2APIK3R1PIK3CAPGR | |
| SCHEMBL4049940 | 0.81 | PIK3R1 (0.46) | NFE2L2ADORA2APIK3R1PIK3CAPGR | |
| SCHEMBL4053726 | 0.81 | UTRN (0.47) | ADORA2AGPR119PIK3R1PIK3CAPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | NFE2L2 996/4885ADORA2A 3069/4885GPR119 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.